Scientists discover a powerful new antivenom hidden in rattlesnake blood — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Maryland researchers found that combining FETUA proteins naturally circulating in western diamondback rattlesnake blood blocked venom about 10 times more effectively than the current sheep-derived commercial rattlesnake antivenom in lab tests.
- Sean B. Carroll, Distinguished University Professor of Biology at UMD, led the study published in the Proceedings of the National Academy of Sciences, building on his lab's 2022 identification of the FETUA-3 protein.
- Individual FETUA proteins each countered specific venom effects — one reduced bleeding, another blocked enzyme activity — but none alone could prevent death from a bite; only optimized combinations achieved complete neutralization.
- The optimized protein mixtures fully neutralized lethal rattlesnake venom and provided broad cross-species protection against multiple vipers, including species separated by millions of years of evolution.
- Elda Sánchez, director of the National Natural Toxins Research Center at Texas A&M University-Kingsville, collaborated with UMD researchers on characterizing what each FETUA protein contributes to venom resistance.
- Carroll expects the first commercial applications of "nature's antivenom" to appear in veterinary medicine, with treatments for human snakebites potentially following later.
- The World Health Organization estimates venomous snakes kill 80,000 to 140,000 people annually, with hundreds of thousands more left permanently disabled — disproportionately in rural areas where effective antivenom is hardest to obtain.
Why it matters: Current antivenoms are produced by injecting large animals with venom and harvesting antibodies, a process that drives high cost, variable quality, and sometimes serious immune reactions — and the WHO estimates these limitations contribute to 80,000–140,000 deaths annually. A recombinant, snake-derived alternative that's roughly 10 times more potent in the lab and broadly active across viper species could meaningfully reshape treatment access in the rural regions where most snakebite fatalities happen, though human trials and scaled manufacturing remain ahead.
Ask SkimNews
